Madrigal Pharmaceuticals (MDGL) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free MDGL Stock Alerts $220.06 +2.89 (+1.33%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 4:24 AM | insidertrades.comFred B. Craves Sells 22,489 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) StockMay 15, 2024 | finance.yahoo.comJohn Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent RoleMay 14, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) PT Lowered to $200.00 at B. RileyMay 13, 2024 | americanbankingnews.comFY2028 EPS Estimates for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Decreased by AnalystMay 13, 2024 | americanbankingnews.comB. Riley Comments on Madrigal Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:MDGL)May 11, 2024 | americanbankingnews.comLeerink Partnrs Brokers Reduce Earnings Estimates for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 10, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) PT Lowered to $200.00B. Riley cut their price target on Madrigal Pharmaceuticals from $270.00 to $200.00 and set a "neutral" rating on the stock in a research note on Friday.May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Start for RezdiffraMay 10, 2024 | marketbeat.comLeerink Partnrs Comments on Madrigal Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:MDGL)Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities research analysts at Leerink Partnrs cut their Q2 2024 earnings per share estimates for Madrigal Pharmaceuticals in a research note issued on Tuesday, May 7th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaMay 10, 2024 | americanbankingnews.comJMP Securities Lowers Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $381.00May 10, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $382.00May 10, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $390.00May 8, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals: Strong Buy Rating Amidst Rapid Growth and Strategic InitiativesMay 8, 2024 | benzinga.comSpotlight on Madrigal Pharmaceuticals: Analyzing the Surge in Options ActivityMay 8, 2024 | finance.yahoo.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $382.00 by Analysts at CitigroupCitigroup reduced their price objective on shares of Madrigal Pharmaceuticals from $389.00 to $382.00 and set a "buy" rating on the stock in a report on Wednesday.May 8, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Misses Expectations By $1.32 EPSMadrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($7.38) EPS for the quarter, missing the consensus estimate of ($6.06) by ($1.32). During the same period in the previous year, the company earned ($4.23) earnings per share.May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Promising Launch of First Approved NASH Treatment and Strong Market PositioningMay 8, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch and Solid FinancialsMay 7, 2024 | seekingalpha.comMadrigal sees ‘tremendous interest’ in new NASH drug RezdiffraMay 7, 2024 | msn.comMDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $235.57Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $235.57May 7, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra LaunchMay 7, 2024 | globenewswire.comMadrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesMay 5, 2024 | marketbeat.comCalifornia Public Employees Retirement System Reduces Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)California Public Employees Retirement System cut its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 18.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,190 sharApril 30, 2024 | seekingalpha.comMadrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-LabelApril 30, 2024 | marketbeat.comMadrigal Pharmaceuticals (MDGL) Scheduled to Post Quarterly Earnings on TuesdayMadrigal Pharmaceuticals (NASDAQ:MDGL) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=587770)April 28, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - MDGLApril 26, 2024 | seekingalpha.comSagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment OpportunityApril 25, 2024 | msn.comMadrigal Pharmaceuticals to Unveil First-Quarter Results, Hosts Live WebcastApril 24, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6%Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 6%April 24, 2024 | globenewswire.comMadrigal Statement on the Passing of Dr. Stephen HarrisonApril 24, 2024 | seekingalpha.comMadrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' AdvantageApril 23, 2024 | finance.yahoo.comMadrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024April 22, 2024 | markets.businessinsider.comUnited Healthcare’s Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy RatingApril 22, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Earns Underperform Rating from Analysts at Bank of AmericaBank of America started coverage on shares of Madrigal Pharmaceuticals in a research note on Monday. They issued an "underperform" rating and a $150.00 target price for the company.April 21, 2024 | marketbeat.comKnights of Columbus Asset Advisors LLC Acquires 4,386 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Knights of Columbus Asset Advisors LLC boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 101.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,695 shares of the biophaApril 20, 2024 | msn.comMadrigal Pharmaceuticals Welcomes New Employees with Equity AwardsApril 17, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 3.3%Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 3.3%April 16, 2024 | globenewswire.comMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 15, 2024 | investorplace.com7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024April 14, 2024 | marketbeat.com211,488 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by AlpInvest Partners B.V.AlpInvest Partners B.V. acquired a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 211,488 shares of the biopharmaceutical company's stock,April 11, 2024 | insidertrades.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub Sells 2,676 SharesApril 11, 2024 | insidertrades.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 26,270 Shares of StockApril 10, 2024 | msn.comMadrigal Pharmaceuticals Launches Rezdiffra, a Pioneer in NASH TreatmentApril 10, 2024 | msn.com2 Under-the-Radar Growth Stocks to ConsiderApril 10, 2024 | fool.com2 Under-the-Radar Growth Stocks to ConsiderApril 10, 2024 | marketbeat.comMoody Aldrich Partners LLC Sells 4,356 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Moody Aldrich Partners LLC lessened its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 32.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,223 shares of the biopharmacApril 9, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent Nvidia Warning (Ad)Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space. Click here to access… MDGL Media Mentions By Week MDGL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDGL News Sentiment▼-0.290.42▲Average Medical News Sentiment MDGL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDGL Articles This Week▼126▲MDGL Articles Average Week Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alkermes News Today Ionis Pharmaceuticals News Today Amicus Therapeutics News Today Geron News Today Rocket Pharmaceuticals News Today Ligand Pharmaceuticals News Today Dynavax Technologies News Today MannKind News Today Y-mAbs Therapeutics News Today Generation Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDGL) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
